Imugene Limited (ASX:IMU) CEO Leslie Chong presents at the FNN Small Cap Investor Event, October 2017, Sydney.
· Imugene’s technology can induce a patient’s body to make its own specific antibodies that target cancer.
· Total monoclonal antibody market is currently at US$60 billion
· Experienced management & board
· Lead mimotope: HER-Vaxx Phase 1b/2 mimotope study in Her2+ gastric cancer (large unmet medical need by current existing therapies)
· POC demonstrated in Phase 1 Her-2+ breast cancer study – safety & immunogenecity established
· Discovery Pipeline: Mimotope candidate selection and Arginine modulators in pre-clinical development
· Numerous milestone announcements & valuation inflection points over next 12-18 months